Leustatin — Competitive Intelligence Brief

Leustatin (CLADRIBINE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Purine Antimetabolite [EPC]. Area: Oncology.

marketed Purine Antimetabolite [EPC] cAMP-specific 3',5'-cyclic phosphodiesterase 4A Oncology Small molecule

Target snapshot

Leustatin (CLADRIBINE). Leustatin works by inhibiting the enzyme that breaks down cyclic adenosine monophosphate (cAMP), leading to an accumulation of cAMP and subsequent activation of various cellular pathways.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Leustatin TARGET	CLADRIBINE		marketed	Purine Antimetabolite [EPC]	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	1993-01-01
Ketas	IBUDILAST	Kyorin Pharmaceutical	marketed	ibudilast	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	1989-01-01
Otezla	Otezla	L.H. Kircik, M.D.	marketed		cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4C
Imuran	AZATHIOPRINE	Legacy Pharma	marketed	Purine Antimetabolite [EPC]	ATP-binding cassette sub-family G member 2	1968-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2038-11-23 — Leustatin · 10849919 · Method of Use · US
• 2041-09-10 — Leustatin · 12533408 · Method of Use · US
• 2041-09-10 — Leustatin · 12539329 · Method of Use · US

Sponsor landscape (Purine Antimetabolite [EPC] class)

1. · 1 drug in this class
2. Legacy Pharma · 1 drug in this class